Athersys (NASDAQ:ATHX) has been given a $6.00 price target by analysts at Maxim Group in a research report issued to clients and investors on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price objective suggests a potential upside of 272.67% from the stock’s previous close.
Separately, ValuEngine lowered Athersys from a “hold” rating to a “sell” rating in a research report on Tuesday, December 5th.
Athersys (NASDAQ ATHX) traded down $0.03 during trading hours on Tuesday, hitting $1.61. The company’s stock had a trading volume of 487,790 shares, compared to its average volume of 573,536. The firm has a market cap of $190.84, a price-to-earnings ratio of -6.19 and a beta of -0.87. Athersys has a 52-week low of $1.08 and a 52-week high of $2.63.
Several large investors have recently bought and sold shares of the business. Bank of New York Mellon Corp increased its position in shares of Athersys by 7.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 284,540 shares of the biopharmaceutical company’s stock worth $430,000 after purchasing an additional 19,375 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Athersys by 34.2% during the 2nd quarter. Rhumbline Advisers now owns 110,064 shares of the biopharmaceutical company’s stock worth $166,000 after acquiring an additional 28,030 shares during the period. NEXT Financial Group Inc boosted its stake in shares of Athersys by 31.6% during the 3rd quarter. NEXT Financial Group Inc now owns 128,950 shares of the biopharmaceutical company’s stock worth $280,000 after acquiring an additional 31,000 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Athersys by 35.3% during the 3rd quarter. Wells Fargo & Company MN now owns 167,176 shares of the biopharmaceutical company’s stock worth $345,000 after acquiring an additional 43,600 shares during the period. Finally, Perkins Capital Management Inc. boosted its stake in shares of Athersys by 17.7% during the 4th quarter. Perkins Capital Management Inc. now owns 363,375 shares of the biopharmaceutical company’s stock worth $658,000 after acquiring an additional 54,650 shares during the period. 20.20% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “Athersys (ATHX) Given a $6.00 Price Target at Maxim Group” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.americanbankingnews.com/2018/02/13/athersys-athx-given-a-6-00-price-target-at-maxim-group.html.
Athersys Company Profile
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.